Table 3.
Category and reason | Phase I (N = 9) | Phase II (N = 38) |
---|---|---|
Discontinuation in multiple-dose period (early termination), n (%) | ||
Adverse event | 0 | 5 (13.2) |
Worsening of disease | 1 (11.1) | 5 (13.2) |
Withdrawal by subject | 0 | 2 (5.3) |
Discontinuation in overall study, n (%) | ||
Adverse event | 0 | 8 (21.1) |
Worsening of disease | 5 (55.6) | 18 (47.4) |
Withdrawal by subject | 0 | 2 (5.3) |